Beck-Nielsen SS, Mughal Z, Haffner D et al (2019) FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis. https://doi.org/10.1186/s13023-019-1014-8

Article  PubMed  PubMed Central  Google Scholar 

Ackah SA, Imel EA (2023) Approach to hypophosphatemic rickets. J Clin Endocrinol Metab 108:209–220. https://doi.org/10.1210/clinem/dgac488

Article  Google Scholar 

Fukumoto S (2021) FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment. J Mol Endocrinol 66:R57–R65

Article  CAS  PubMed  Google Scholar 

Carpenter TO, Imel EA, Holm IA et al (2011) A clinician’s guide to X-linked hypophosphatemia. J Bone Miner Res 26:1381–1388

Article  PubMed  Google Scholar 

Chesher D, Oddy M, Darbar U et al (2018) Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations. J Inherit Metab Dis 41:865–876. https://doi.org/10.1007/s10545-018-0147-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Whyte MP, Greenberg CR, Salman NJ et al (2012) Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med 366:904–913. https://doi.org/10.1056/nejmoa1106173

Article  CAS  PubMed  Google Scholar 

Linglart A, Imel EA, Whyte MP et al (2022) Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia. J Clin Endocrinol Metab 107:813–824. https://doi.org/10.1210/clinem/dgab729

Article  PubMed  Google Scholar 

Linglart A, Biosse-Duplan M, Briot K et al (2014) Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect 3:R13–R30. https://doi.org/10.1530/ec-13-0103

Article  PubMed  PubMed Central  Google Scholar 

Wang S, Wang X, He M et al (2023) Efficacy and safety of burosumab in X-linked hypophosphatemia. J Clin Endocrinol Metab 109(1):293–302. https://doi.org/10.1210/clinem/dgad440

Article  PubMed  Google Scholar 

Insogna KL, Briot K, Imel EA et al (2018) A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res 33:1381–1382

Article  Google Scholar 

Carpenter TO, Imel EA, Ruppe MD et al (2014) Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Investig 124:1587–1597. https://doi.org/10.1172/JCI72829

Article  CAS  PubMed  PubMed Central  Google Scholar 

Padidela R, Whyte MP, Glorieux FH et al (2021) Patient-reported outcomes from a randomized, active-controlled, open-label, phase 3 trial of burosumab versus conventional therapy in children with X-linked hypophosphatemia. Calcif Tissue Int 108:622–633. https://doi.org/10.1007/s00223-020-00797-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097

Article  PubMed  PubMed Central  Google Scholar 

www.metaxis.com. PROSPERO International prospective register of systematic reviews

Thacher TD, Pettifor JM, Tebben PJ et al (2019) Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: utility of the radiographic rickets severity score. Bone 122:76–81. https://doi.org/10.1016/j.bone.2019.02.010

Article  PubMed  Google Scholar 

Thacher TD, Fischer PR, Pettifor JM et al (2000) Radiographic scoring method for the assessment of the severity of nutritional rickets. J Trop Pediatr 46:132–139. https://doi.org/10.1093/tropej/46.3.132

Article  CAS  PubMed  Google Scholar 

Bellamy NBWGCCJSLW (1998) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15:1833–1840

Google Scholar 

Rohatgi A (2021) WebPlotDigitizer Pacifica, California, USA [07/11/2021]. Version: 4.5. Available from: https://automeris.io/WebPlotDigitizer

Higgins JPT, Li T, Deeks JJ (eds) (2023) Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane. Available from www.training.cochrane.org/handbook

Deeks JJ, Higgins JPT, Altman DG (eds) (2023) Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane. Available from www.training.cochrane.org/handbook

Sterne JA, Hernán MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ (Online) 355:i4919. https://doi.org/10.1136/bmj.i4919

Article  PubMed  Google Scholar 

Sterne JAC, Hernán MA, McAleenan A, Reeves BC, Higgins JPT (2023) Chapter 25: Assessing risk of bias in a non-randomized study. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane. Available from www.training.cochrane.org/handbook

Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G et al (2016) Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods 7(1):55–79

Article  PubMed  Google Scholar 

Sandy J (2019) Abstracts. Horm Res Paediatr 91:1–682. https://doi.org/10.1159/000501868

Article  Google Scholar 

Shammari AA (2021) Abstracts. Horm Res. Paediatr 94:1–445. https://doi.org/10.1159/000518849

Article  CAS  Google Scholar 

Baroncelli G (2022) Abstracts. Horm Res Paediatr 96:40

Google Scholar 

Zhukouskaya V (2019) Abstracts. Horm Res Paediatr 91:1–682

Article  Google Scholar 

Arcidiacono T, Foligno NE, Brioni E et al (2023) Different efficacy of burosumab on physical performance and serum phosphate in adult patients with X-linked hyphophosphatemic rickets during the first six-month of treatment. J Clin Med 12(8):2906. https://doi.org/10.3390/jcm12082906

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brener A, Lebenthal Y, Cleper R et al (2021) Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy. Ther Adv Endocrinol Metab. https://doi.org/10.1177/20420188211001150

Article  PubMed  PubMed Central  Google Scholar 

Weber TJ, Imel EA, Carpenter TO et al (2023) Long-term burosumab administration is safe and effective in adults with X-linked hypophosphatemia. J Clin Endocrinol Metab 108:155–165. https://doi.org/10.1210/clinem/dgac518

Article  Google Scholar 

Whyte MP, Carpenter TO, Gottesman GS et al (2019) Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol 7:189–199. https://doi.org/10.1016/S2213-8587(18)30338-3

Article  PubMed  Google Scholar 

Imel EA, Zhang X, Ruppe MD et al (2015) Prolonged correction of serum phosphorus in adults with x-linked hypophosphatemia using monthly doses of KRN23. J Clin Endocrinol Metab 100:2565–2573. https://doi.org/10.1210/jc.2015-1551

Article  CAS  PubMed  PubMed Central  Google Scholar 

Insogna KL, Rauch F, Kamenický P et al (2019) Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial. J Bone Miner Res 34:2183–2191. https://doi.org/10.1002/jbmr.3843

Article  CAS  PubMed  Google Scholar 

Namba N, Kubota T, Muroya K et al (2022) Safety and efficacy of burosumab in pediatric patients with X-linked hypophosphatemia: a phase 3/4 open-label trial. J Endocr Soc. https://doi.org/10.1210/jendso/bvac021

Article  PubMed  PubMed Central  Google Scholar 

Paloian NJ, Nemeth B, Sharafinski M et al (2022) Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets. Pediatr Nephrol 37:2667–2677. https://doi.org/10.1007/s00467-022-05484-7

Article  PubMed  Google Scholar 

Ruppe MD, Zhang X, Imel EA et al (2016) Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia. Bone Rep 5:158–162.